---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-035117"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:27:38.649459+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Provectus Board decides not to execute reverse stock split in 2022; plans to seek approval again in 2023

## Summary
- Board decided not to undertake the reverse stock split and authorized share reduction approved at 2022 Annual Meeting.
- Decision based on prospective factors and potential negative capital markets behavior, per Chair Ed Pershing.
- Board expects to seek same stockholder approval again in 2023 at a special or annual meeting.
- Provectus trades on OTCQB under ticker PVCT.

## SEC filing metadata
- accession: 0001493152-22-035117
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315222035117/0001493152-22-035117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315222035117/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-035117
- JSON: https://secwatch.observer/filing/0001493152-22-035117.json
- Plain text: https://secwatch.observer/filing/0001493152-22-035117.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.